AmpliSeq for Illumina Focus Panel
Key features:
- Relevant Gene Content- Target biomarkers across 52 genes relevant to solid tumors
- Fast, Streamlined Workflow- Prepare sequencing-ready libraries in a single day from as little as 1 ng of high quality or 10 ng of formalin-fixed, paraffin embedded (FFPE) input samplels
- Accurate Data- Detect somatic mutations down to 5% of frequency using local or cloud-based analysis
AmpliSeq for Illumina BRCA Panel
- Relevant Gene Content- Target all exonic regions and flanking intronic sequences of BRCA1 and BRCA2
- Fast, Streamlined Workflow- Prepare sequencing-ready libraries in a single day from as little as 1 ng of high quality or 10 ng of formalin-fixed, paraffin-embedded (FFPE) input samples
- Accurate Data- Detect somatic mutations as low as 5% variant allele frequency using local or cloud based analysis
AmpliSeq for Illumina Myeloid Panel
Key features include:
- High-Value Content- Targets biomarkers across 69 genes including challenging targets such as CEBPA and FLT3-ITDs
- Fast, Streamlined Workflow- Prepare sequencing-ready libraries in a single day from as little as 10 ng high quality DNA and RNA
- Accurate Data- Detect somatic mutations down to 5% frequency using local or cloud-based analysis
TruSight Cancer
- Targets 94 genes and 284 SNPs associated with a predisposition towards cancer
TruSight Cancer includes genes associated with both common (e.g., breast, colorectal) and rare cancers. In addition, the set includes 284 SNPs found to correlate with cancer through genome-wide association studies (GWAS). Content selection was based on expert curation of the scientific literature and other high-quality resources.
The TruSight Cancer sequencing panel provides custom oligos targeting identified regions of interest. Sufficient product is supplied for four enrichment reactions.
TruSight Tumor 15
Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.
This TruSight Tumor panel offers:
- Comprehensive workflow: Assess 15 genes with one simple workflow instead of single, iterative gene testing with polymerase chain reaction (PCR)
- Efficient: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
- Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1,2, key opinion leaders3,4, and pharmaceutical research
- Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples
TruSight Oncology 500
TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables Comprehensive Genomic Profiling of tumor samples. It supports identification of all relevant DNA and RNA* variants implicated in various tumor types.
In addition, it accurately measures the key immunotherapy biomarkers: tumor mutation burden (TMB) and microsatellite instability (MSI).
Save Time, Money, and Samples through assay Consolidation
- Pan-cancer content aligned with key guidelines and clinical trials
- DNA + RNA* assay targeting 523 genes for assessment of small variants, TMB, MSI, splice variants, and fusions
- Identify relevant alterations while achieving highly accurate results
Achieve Highly Confident Results
- Software filters artifacts for accurate variant calling
- Enrichment chemistry inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
- Based on proven Illumina platform
Unlock Immuno-Oncology
- Panel contains immuno-oncology biomarkers TMB and MSI
- Tumor-only workflow for simplicity and efficiency
- TMB calling performance similar to whole-exome sequencing (WES) panels
- Large 1.94 Mb panel and sophisticated algorithm for accurate TMB score
* The product to evaluate DNA & RNA variants is the TSO500 DNA/RNA bundle.
TruSight One Sequencing Panels
- Two panels offer options to target up to 6700 genes associated with human disease, with high coverage
- Single assay includes multiple genes of interest, replacing iterative testing
- Easy, flexible gene filtering and annotation options simplify biological interpretation and reporting
TruSight Cardio Sequencing Kit
Product Highlights:
- Expertly defined genes selected in collaboration with the Imperial College of London
- 99% of the targeted regions covered at a depth of at least 20x*
- Cost to sequence is ~&1 US per gene; fully supported on Illumina sequencing and informatics platforms
VeriSeq PGS
- Industry-leading data quality- More than 90% of the world’s sequencing data is generated by Illumina sequencing by synthesis (SBS) chemistry
- Fast, streamlined workflow- Sample to answer in approximately 12 hours
- High-throughput analysis: Screen up to 24 samples per run
Solid Tumor Solution by SOPHiA GENETICS
The STS panel covers the coding regions and splicing junctions (±25 bp min) of 42 genes, associated but not limited to lung and colorectal cancers, melanoma and glioma. It guarantees superior coverage uniformity, high on-target reads percentage and exceptional coverage in GC-rich regions, even in the first exon.
Solid Tumor Plus Solution by SOPHiA GENETICS
Myeloid Solution™ by SOPHiA GENETICS
Myeloid Plus Solution by SOPHiA GENETICS
Hereditary Cancer Solution by SOPHiA GENETICS
SOPHiA Cardio Solution™
SOPHiA Extended Cardio Solution™
Devyser Thalassemia NGS
This simple workflow significantly reduces the risk for contamination and sample mix-up. Reliable detection of large structural deletion is further improved through the use of PCR primers aligned to both ends of 18 large deletions with high prevalence. Simultaneously, coverage based CNV analysis is used to confirm detected deletions and to identify additional large structural deletions in the targeted regions
Key Features
- Complete one-tube analysis – Single-tube NGS method for both SNV and CNV detection in HBA1, HBA2 and HBB
- Fast and simple NGS workflow – From DNA to sequencing in less than 5 hours with less than 45 mins hands-on time
- User-friendly data analysis software – Bypass complex and laborious data analysis with ourtailored analytical software solution
Devyser BRCA NGS
The proprietary multiplex PCR primer chemistry provides full and uniform coverage of both BRCA1 and BRCA2, covering all coding exons and exon/intron junctions. The kit uses overlapping primer design to ascertain superior indel coverage and downstream CNV analysis. The Devyser BRCA kit can be used to detect both germline and somatic mutations.
Key Features:
- Detect all mutations in BRCA1 and BRCA2 – Detects SNVs, indels and exon-spanning CNVs
- One tube per sample – No need for sample splitting, reduce hands-on time from days to under 45 minutes & minimizes the risk of sample mix-up and contamination
- Flexible batching size – Able to run 8, 24 & 96 samples in a cost-effective manner with lower number of samples
- One kit for both germline and somatic mutations
- Choice of several validated software options, including CNV analysis